SEC Comment Letter 0000000000-26-005952 to Onconetix, Inc. (ONCO)
Onconetix, Inc.
Date: June 12, 2026 · CIK: 0001782107 · Accession: 0000000000-26-005952
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296615
Letter
June 12, 2026 David A. White Chief Executive Officer Onconetix, Inc. 201 E. Fifth Street, Suite 1900 Cincinnati, Ohio 45202 Re: Onconetix, Inc. Registration Statement on Form S-1 Filed June 9, 2026 File No. 333-296615 Dear David A. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica Yuan, Esq.
Show Raw Text
June 12, 2026 David A. White Chief Executive Officer Onconetix, Inc. 201 E. Fifth Street, Suite 1900 Cincinnati, Ohio 45202 Re: Onconetix, Inc. Registration Statement on Form S-1 Filed June 9, 2026 File No. 333-296615 Dear David A. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica Yuan, Esq.